Short-term preseasonal immunotherapy with birch pollen allergoid plus monophosphoryllipid A (MPL) - Influence on cytokine production of peripheral T cells in patients with allergic rhinitis

Allergy and Clinical Immunology International

Volumn 16, Issue 2, 2004, Pages 60-64

  Stuck, Boris A ^a   Schneider Gene, Solange ^a   Schäfer, Dirk ^a   Klimek, Ludger ^a   Hörmann, Karl ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Allergoids; Cytokine production; Immunotherapy; Monophosphoryllipid A

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 5; PHOSPHORYL LIPID A; PLACEBO; POLINEX QUATTRO; POLLEN ANTIGEN; TYROSINE;

ADULT; ALLERGIC RHINITIS; ARTICLE; BIRCH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; HUMAN; IMMUNOMODULATION; IMMUNOPOTENTIATION; IMMUNOTHERAPY; INJECTION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; PERIPHERAL LYMPHOCYTE; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

EID: 1642483055     PISSN: 08381925     EISSN: None     Source Type: Journal    
DOI: 10.1027/0838-1925.16.2.60     Document Type: Article

References (26)

1. Bousquet J, Becker WM, Hejjaoui A et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species. II. Efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts. J Allergy Clin Immunol 1991; 88:43-53
2. Walker SM, Varney VA, Gaga M et al. Grass pollen immunotherapy: Efficacy and safety during a 4-year follow-up study. Allergy 1995; 50:405-413
3. Grammer LC, Shaughnessy MA, Bernhard MI et al. The safety and activity of polymerized ragweed: A double-blind, placebo-controlled trial in 81 patients with ragweed rhinitis. J Allergy Clin Immunol 1987; 80:177-183
4. Balda BR, Wolf H, Baumgarten C et al. Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens. Allergy 1998; 53:740-748
5. Klimek L, Wolf H, Mewes T et al. The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions. J Allergy Clin Immunol 1999; 103:47-53
6. Bachert C, Wagenmann M, Holtappels G. Cytokines and adhesion molecules in allergic rhinitis. Am J Rhinol 1998; 12:3-8
7. Keskin G, Inal A, Ali Sari R et al. Serum IFN-gamma and IL-10 levels before and after specific immunotherapy in patients with allergic rhinitis. Allergol Immunopathol (Madr) 1999; 27:261-264
8. Lee CH, Rhee CS, Oh SH et al. Increase in expression of IL-4 and IL-5 mRNA in the nasal mucosa of patients with perennial allergic rhinitis during natural allergen exposure. Ann Otol Rhinol Laryngol 1997; 106:215-219
9. Maggi E, Parronchi P, Manetti R et al. Reciprocal regulatory effects of IFN-gamma and IL-4 on the in vitro development of human Th1 and Th2 clones. J Immunol 1992; 148:2142-2147
10. Masamoto T, Ohashi Y, Nakai Y. Specific immunoglobulin E, interleukin-4, and soluble vascular cell adhesion molecule-1 in sera in patients with seasonal allergic rhinitis. Ann Otol Rhinol Laryngol 1999; 108:169-176
11. Christodoulopoulos P, Cameron L, Durham S et al. Molecular pathology of allergic disease. II: Upper airway disease. J Allergy Clin Immunol 2000; 105:211-223
12. Maasch HJ, Marsh DG. Standardized extracts modified allergens - Allergoids. Clin Rev Allergy 1987; 5:89-106
13. Klimek L, Dormann D, Jarman ER et al. Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis. Clin Exp Allergy 1999; 29:1326-1335
14. Pastorello EA, Pravettoni V, Incorvaia C et al. Clinical and immunological effects of immunotherapy with alum-absorbed grass allergoid in grass-pollen-induced hay fever. Allergy 1992; 47:281-290
15. De Becker G, Moulin V, Pajak B et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int Immunol 2000; 12:807-815
16. Thoelen S, Van Damme P, Mathei C et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998; 16:708-714
17. van Cauwenberge P, Bachert C, Passalacqua G et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000; 55:116-134
18. Dormann D, Montermann E, Klimek L et al. Heterogeneity in the polyclonal T cell response to birch pollen allergens. Int Arch Allergy Immunol 1997; 114:272 277
19. + T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97:1356-1365
20. Hayashi M, Ohashi Y, Tanaka A et al. Suppression of seasonal increase in serum interleukin-5 is linked to the clinical efficacy of immunotherapy for seasonal allergic rhinitis. Acta Otolaryngol Suppl 1998; 538:133-142
21. Benjaponpitak S, Oro A, Maguire P et al. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. J Allergy Clin Immunol 1999; 103:468-475
22. + T cells from allergic individuals. J Exp Med 1993; 178:2123-2130
23. Ito H, Suzuki M, Mamiya S et al. Study on changes in the level of serum IL-4 and soluble CD 23 (s-CD23) with immunotherapy in nasal allergy patients. Acta Otolaryngol Suppl 1996; 525:98-104
24. Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ, Kay AB, Durham SR. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92:644-651
25. Kakinoki Y, Ohashi Y, Nakai Y et al. Pollen immunotherapy inhibits T helper 1 and 2 cell responses, but suppression of T helper 2 cell response is a more important mechanism related to the clinical efficacy. Arch Otolaryngol Head Neck Surg 2000; 126:63-70
26. Baldridge JR, Yorgensen Y, Ward JR, Ulrich JT. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 2000; 18:2416-2425.